Profil bibliographique

Enriqueta Felip

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

8Publications signalées

6Citations signalées

2Affiliations récentes

Institutions déclarées

Vall d'Hebron Hospital Universitari Vall d'Hebron Institute of Oncology

Domaines associés

Lung Cancer Treatments and MutationsMelanoma and MAPK PathwaysLung Cancer Research StudiesCancer Immunotherapy and BiomarkersHER2/EGFR in Cancer Research

Publications récentes

Accès ouvert 2026 conference-abstractOpenAlex

First-line (1L) divarasib plus pembrolizumab (pembro) in advanced or metastatic KRAS G12C+ non–small cell lung cancer (NSCLC): Results from the Krascendo-170 study.

Ferdinandos Skoulidis, Kristof Cuppens, Willemijn S.M.E. Theelen, Caicun Zhou et autres

1 citationJournal of Clinical Oncology

Accès ouvert 2026 conference-abstractOpenAlex

ALKOVE-1: Efficacy and safety of neladalkib in patients with advanced ALK + NSCLC.

Jessica Jiyeong Lin, Enriqueta Felip, B K Cho, B Besse et autres

2 citationsJournal of Clinical Oncology

2026 conference-abstractOpenAlex

Lorlatinib vs crizotinib as first-line treatment for advanced ALK + non-small cell lung cancer: 7-year update from the phase 3 CROWN study.

Tony S.K. Mok, Benjamin J. Solomon, Enriqueta Felip, Todd M. Bauer et autres

1 citationJournal of Clinical Oncology

2026 conference-abstractOpenAlex

Efficacy and safety of pralsetinib as first-line treatment of RET fusion–positive advanced or metastatic non–small cell lung cancer (NSCLC): The phase 3 AcceleRET-Lung study.

Sanjay Popat, B Besse, A Calles, Fabiana Letizia Letizia Cecere et autres

2 citationsJournal of Clinical Oncology

2026 conference-abstractOpenAlex

First-in-human dose-escalation study of the selective EGFR/HER2 exon 20 inhibitor PFL-721 in patients with locally advanced or metastatic NSCLC.

Anas Gazzah, Chia-Chi Lin, Gerrina Ruiter, Ki Hyeong Lee et autres

0 citationsJournal of Clinical Oncology

2026 conference-abstractOpenAlex

Final analysis of the biomarker-directed, randomized, phase 2 KEYNOTE-495/KeyImPaCT study of pembrolizumab (P)–based combination therapy for non–small cell lung cancer (NSCLC).

Martin Gutierrez, Wei‐Sen Lam, Adam J. Schoenfeld, Matthew A. Gubens et autres

0 citationsJournal of Clinical Oncology

2026 conference-abstractOpenAlex

Sex-specific trends and outcomes in small cell lung cancer (SCLC) in Spain: Insights from the CLARISSE study (2019–2024).

P Garrido, N. Villanueva, Reyes Bernabé, Rosario García Campelo et autres

0 citationsJournal of Clinical Oncology

2026 conference-abstractOpenAlex

Zidesamtinib efficacy and safety in patients with advanced ROS1 -positive solid tumors other than NSCLC in the ARROS-1 study.

Benjamin J. Solomon, Sanjay Popat, Enriqueta Felip, Alexander E. Drilon et autres

0 citationsJournal of Clinical Oncology

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.